Source: Eur Respir J 2007; 29: 423-427



Rating:

Share or cite this content

Citations should be made in the following way:
Migliori G. B., Loddenkemper R., Blasi F., Raviglione M. C.. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is science enough to tackle the epidemic?. Eur Respir J 2007; 29: 423-427

Member's Comments

No comment yet.

Related content which might interest you: Managing an extensively drug-resistant tuberculosis outbreak: the public health face of the medal Source: Eur Respir J 2015; 45: 292-294 Year: 2015 Multidrug-resistant tuberculosis around the world: what progress has been made? Source: Eur Respir J 2015; 45: 150-160 Year: 2015 Escaping the Plato's cave of latent tuberculosis testing: a path for developers of predictive tests for risk of tuberculosis Source: Eur Respir J, 52 (4) 1801616; 10.1183/13993003.01616-2018 Year: 2018 Towards the elimination of tuberculosis: challenges ahead from a European perspective Source: Annual Congress 2012 - Joint session with WHO and ECDC "Towards elimination of tuberculosis" Year: 2012 TB "cross-border" - a new challenge in tuberculosis management Source: Virtual Congress 2020 – Tuberculosis and society Year: 2020 The global response to rifampicin-resistant tuberculosis: Current situation and recent trends Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 Managing difficult TB cases: experiences from the ERS/WHO TB Consilium and other country-specific Consilia Source: International Congress 2017 – In the frontline of the fight against tuberculosis Year: 2017 Childhood tuberculosis: a concern of the modern world Source: Eur Respir Rev 2014; 23: 278-291 Year: 2014 Translating scientific discoveries during pandemics: ensuring equity for people affected by COVID-19 and tuberculosis Source: ERJ Open Res, 6 (4) 00562-2020; 10.1183/23120541.00562-2020 Year: 2020 The top of the iceberg - Extensively drug resistant tuberculosis (XDR-TB) in 2010 Source: International Congress 2015 – Epidemiology of TB: deaths, co-morbidities, migration and children Year: 2015 Childhood tuberculosis: progress requires an advocacy strategy now Source: Eur Respir J 2012; 40: 294-297 Year: 2012 Multidrug-resistant and extensively drug resistance tuberculosis has a strong public health and economical impact in the Republic of Moldova Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection in subpopulations Year: 2013 Treatment of multidrug-resistant tuberculosis in Uzbekistan from 2012 to 2018: does practice follow policy? Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021 The particularities of new cases of tuberculosis at homeless people Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management II Year: 2013 Tuberculosis elimination, patients' lives and rational use of new drugs: revisited Source: Eur Respir J 2016; 47: 664-667 Year: 2016 Novel drugs against tuberculosis: a clinician's perspective Source: Eur Respir J 2015; 45: 1119-1131 Year: 2015 Tuberculosis elimination in Oman: winning the war on the disease Source: ERJ Open Res, 4 (4) 00121-2018; 10.1183/23120541.00121-2018 Year: 2018 Minimum package for cross-border TB control and care in the WHO European region: a Wolfheze consensus statement Source: Eur Respir J 2012; 40: 1081-1090 Year: 2012 DOTS strategy - key for the progress in the control of TB; five years of experience in Iasi County Source: Eur Respir J 2004; 24: Suppl. 48, 724s Year: 2004